您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > TAE-1
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
TAE-1
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
TAE-1图片
CAS NO:1414469-59-2
规格:98%
分子量:1128.6
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议
25mg电议

产品介绍
inhibitor of amyloid-β fibril formation and aggregation
CAS:1414469-59-2
分子式:C39H51N6O9 ? 3I
分子量:1128.6
纯度:98%
存储:Store at -20°C

Background:

IC50: 0.3 ± 0.02 μM for AChE; 3.9 ± 0.2 μM for BuChE


TAE-1 is an inhibitor of amyloid-β fibril formation and aggregation.


Alzheimer’s disease (AD), a progressive neurodegenerative disorder, is characterized by the cerebral accumulation of insoluble aggregates of amyloid-β peptides (Aβ). Although the precise mechanisms governing neuronal loss remains ambiguous, toxicity resulting from Aβ-activated pathways is evident.


In vitro: In a previous study, the authors examined the effects of TAE-1 on differentiated human SH-SY5Y neuronal cells grown in tissue culture. Results showed that the stimulation of neuronal cellular process length and branching was noted. Moreover, the increased synaptophysin suggested that TAE-1 could stimulate synapse formation. Increased expression of MAP2 was also observed, indicating that TAE-1 promoted the differentiation of human neurons. In addition, targeted AChE inhibition was evaluated by electrochemical quantification of the enzymatic product, thiocholine, on unmodified gold screen-printed electrodes. It was found that at increasing TAE-1concentrations, there was a corresponding decrease in the AChE activity resulting in reduced amount of oxidizable thiocholine. The IC50 value was found to be 0.465 μM for TAE-1 [1].


In vivo: Up to now, there is no animla in vivo data reported.


Clinical trial: So far, no clinical study has been conducted.


Reference:
[1] Veloso AJ, Chow AM, Dhar D, Tang DW, Ganesh HV, Mikhaylichenko S, Brown IR, Kerman K. Biological activity of sym-triazines with acetylcholine-like substitutions as multitarget modulators of Alzheimer's disease. ACS Chem Neurosci. 2013 Jun 19;4(6):924-9.